Gender, Brain-Derived Neurotrophic Factor Val66Met, and Frequency of Methamphetamine Use

Heinzerling, Keith G.; Shoptaw, Steven

doi:10.1016/j.genm.2012.02.005

Cited by 22 publications

(12 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 15 , 16 Moreover, BDNF could dose-dependently block the METH-induced neuronal cell death in vitro and altered BDNF expression could reduce METH induced striatal dopamine depletion in mice. 32 Taken together, the increased BDNF levels following METH may be a protective response against the subsequent METH-induced neurotoxicity, and DA may be an important mediating factor that involved in the regulation of BDNF expression following exposure to METH.…”

Section: Discussionmentioning

confidence: 98%

Time-Dependent Serum Brain-Derived Neurotrophic Factor Decline During Methamphetamine Withdrawal

et al. 2016

View full text Add to dashboard Cite

Methamphetamine (METH) is a widely abused illegal psychostimulant, which is confirmed to be neurotoxic and of great damage to human. Studies on the role of brain-derived neurotrophic factor (BDNF) in human METH addicts are limited and inconsistent. The purposes of this study are to compare the serum BDNF levels between METH addicts and healthy controls during early withdrawal, and explore the changes of serum BDNF levels during the first month after METH withdrawal.179 METH addicts and 90 age- and gender-matched healthy controls were recruited in this study. We measured serum BDNF levels at baseline (both METH addicts and healthy controls) and at 1 month after abstinence of METH (METH addicts only).Serum BDNF levels of METH addicts at baseline were significantly higher than controls (1460.28 ± 490.69 vs 1241.27 ± 335.52 pg/mL; F = 14.51, P < 0.001). The serum BDNF levels of 40 METH addicts were re-examined after 1 month of METH abstinence, which were significantly lower than that at baseline (1363.70 ± 580.59 vs 1621.41 ± 591.07 pg/mL; t = 2.26, P = .03), but showed no differences to the controls (1363.70 ± 580.59 vs 1241.27 ± 335.52 pg/mL; F = 2.29, P = 0.13).Our study demonstrated that serum BDNF levels were higher in METH addicts than controls during early withdrawal, and were time dependent decreased during the first month of abstinence. These findings may provide further evidence that increased serum BDNF levels may be associated with the pathophysiology of METH addiction and withdrawal and may be a protective response against the subsequent METH-induced neurotoxicity. Besides, these findings may also promote the development of medicine in the treatment of METH addiction and withdrawal.

show abstract

Section: Discussionmentioning

confidence: 98%

Time-Dependent Serum Brain-Derived Neurotrophic Factor Decline During Methamphetamine Withdrawal

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The reasons for this trend may be behavioral or physiological or both. Behaviors modulated by this SNP include addiction [64, 65], aggression [66, 67], participation in high risk sports [68], and hyper-active impulsivity (in people with attention deficit hyperactivity disorder) [69]. Met carriers have greater hostility and aggression, supporting a behavioral explanation for this trend [63].…”

Section: Val66met In Tbimentioning

confidence: 99%

The Influence of the Val66Met Polymorphism of Brain-Derived Neurotrophic Factor on Neurological Function after Traumatic Brain Injury

Finan

Udani

Patel

et al. 2018

JAD

View full text Add to dashboard Cite

Functional outcomes after traumatic brain injury (TBI) vary widely across patients with apparently similar injuries. This variability hinders prognosis, therapy, and clinical innovation. Recently, single nucleotide polymorphism (SNPs) that influence outcome after TBI have been identified. These discoveries create opportunities to personalize therapy and stratify clinical trials. Both of these changes would propel clinical innovation in the field. This review focuses on one of most well-characterized of these SNPs, the Val66Met SNP in the brain-derived neurotrophic factor (BDNF) gene. This SNP influences neurological function in healthy subjects as well as TBI patients and patients with similar acute insults to the central nervous system. A host of other patient-specific factors including ethnicity, age, gender, injury severity, and post-injury time point modulate this influence. These interactions confound efforts to define a simple relationship between this SNP and TBI outcomes. The opportunities and challenges associated with personalizing TBI therapy around this SNP and other similar SNPs are discussed in light of these results.

show abstract

“…Interestingly, BDNF also plays important and diverse roles in addiction-related behaviors (reviewed in (Autry & Monteggia, 2012)). Val/Val carriers may also be at higher risk for methamphetamine abuse (Heinzerling & Shoptaw, 2012). In previous work from our group, the BDNF polymorphism was a significant but weak predictor of white matter integrity in young adulthood (Chiang et al, 2011) – its predictive value was weaker than that of several other genes so far discussed, including CLU and HFE (Kohannim et al, 2012).…”

Section: Neurodegenerative Risk Genes Related To Addictionmentioning

confidence: 99%

Neuroimaging and genetic risk for Alzheimer’s disease and addiction-related degenerative brain disorders

Roussotte¹,

Daianu²,

Jahanshad³

et al. 2013

Brain Imaging and Behavior

View full text Add to dashboard Cite

Neuroimaging offers a powerful means to assess the trajectory of brain degeneration in a variety of disorders, including Alzheimer’s disease (AD). Here we describe how multimodal imaging can be used to study the changing brain during the different stages of AD. We integrate findings from a range of studies using magnetic resonance imaging (MRI), positron emission tomography (PET), functional MRI (fMRI) and diffusion weighted imaging (DWI). Neuroimaging reveals how risk genes for degenerative disorders affect the brain, including several recently discovered genetic variants that may disrupt brain connectivity. We review some recent neuroimaging studies of genetic polymorphisms associated with increased risk for late-onset Alzheimer’s disease (LOAD). Some genetic variants that increase risk for drug addiction may overlap with those associated with degenerative brain disorders. These common associations offer new insight into mechanisms underlying neurodegeneration and addictive behaviors, and may offer new leads for treating them before severe and irreversible neurological symptoms appear.

show abstract

Gender, Brain-Derived Neurotrophic Factor Val66Met, and Frequency of Methamphetamine Use

Cited by 22 publications

References 51 publications

Time-Dependent Serum Brain-Derived Neurotrophic Factor Decline During Methamphetamine Withdrawal

Time-Dependent Serum Brain-Derived Neurotrophic Factor Decline During Methamphetamine Withdrawal

The Influence of the Val66Met Polymorphism of Brain-Derived Neurotrophic Factor on Neurological Function after Traumatic Brain Injury

Neuroimaging and genetic risk for Alzheimer’s disease and addiction-related degenerative brain disorders

Contact Info

Product

Resources

About